The evidence supporting a role for VAR in the treatment of AUD continues to accumulate. We have previously reported that, in rats, VAR reduces alcohol intake when given over prolonged periods of time (Froehlich et al., 2016), when given alone or in combination with naltrexone (Froehlich et al., 2016, 2017), when given prior to initial alcohol exposure (Froehlich et al., 2017) and, in the current study, when given during repeated cycles of alcohol reaccess following alcohol deprivation. The versatility of VAR in reducing alcohol drinking, in a variety of situations, suggests that VAR may be a flexible pharmacotherapeutic agent for the treatment of AUDs.
